U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
SAINT LAURENT, Quebec, May 03, 2018 -- IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2018 financial results after market close on May 10, 2018.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Thursday, May 10, 2018
Time: 4:30 p.m. ET
Conference dial-in: (833) 231-8269
International dial-in: (647) 689-4114
Conference ID: 2398086
Webcast Registration: Click here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 [email protected] Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 [email protected]
